Budesonide dry-powder inhalation - Vectura

Drug Profile

Budesonide dry-powder inhalation - Vectura

Alternative Names: Budesonide Clickhaler

Latest Information Update: 04 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Innovata
  • Developer Innovata; Mylan
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Mar 2015 No recent reports on development identified - Registered for Asthma in New Zealand (Inhalation)
  • 13 May 2013 Budesonide Clickhaler® licensed to Tianjin Kinnovata Pharmaceutical in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top